To characterize their subtypes and activation states in metastatic bone niches and determine ASH1L’s impact, we performed clustering and differential gene expression analyses of monocytes (C3) and TAMs (C4) in control and ASH1L-depleted bone tumors. Here, ASH1L is linked to bone neoplasm.